Lucien Marchand1,2, Yukiko Kawasaki-Ogita1, Jérome Place3, Corinne Fayolle1, Dominique Lauton1, Françoise Boulet1, Anne Farret1,3, Eric Renard1,3. 1. 1 Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, Montpellier, France. 2. 2 Department of Endocrinology, Diabetes, Metabolic Diseases, Hospices Civils de Lyon, Lyon-South University Hospital, Lyon, France. 3. 3 Institute of Functional Genomics, University of Montpellier, Montpellier, France.
Abstract
BACKGROUND: We investigated the long-term effects of continuous subcutaneous insulin infusion (CSII) on glucose control and microvascular complications in patients with type 1 diabetes (T1D). METHODS: A total of 157 patients (59 M/98 W; age 39.1 ± 14.8 years) with T1D who switched from multiple daily injections to CSII and used CSII for at least one year were included. HbA1c levels and status of microvascular complications before and while under CSII were analyzed, retrospectively. RESULTS: The follow-up period was 4.0 ± 1.5 years. HbA1c significantly decreased from 8.4 ± 1.3 to 7.7 ± 1.3% (68 ± 14 to 61 ± 14 mmol/mol) after 1-year CSII and remained lower than pre-CSII levels during four years. Patients with pre-CSII HbA1c >8.0% (64 mmol/mol) showed significant improvement of HbA1c for four years, while those with pre-CSII HbA1c <8.0% showed no significant change. The prevalence of retinopathy, albuminuria, and chronic kidney disease (CKD) were respectively 39%, 12%, and 9% at CSII initiation. During follow-up, the incidence of retinopathy, albuminuria, and CKD were 3.6, 2.5 and 1.4/100 patient-years. Onset or progression of retinopathy occurred in 16 (27.1%) patients with diabetes duration >15 years, and in three (4.3%) patients with diabetes duration <15 years ( P < .01). CONCLUSION: CSII was effective in improving HbA1c for up to four years, specifically in patients with HbA1c >8% (64 mmol/mol) prior to CSII. Incidence and progression rates of retinopathy and albuminuria were low, particularly in patients with a diabetes duration <15 years at CSII initiation. These results argue for not delaying a proposal of CSII initiation in T1D with sustained HbA1c >8% (64 mmol/mol).
BACKGROUND: We investigated the long-term effects of continuous subcutaneous insulin infusion (CSII) on glucose control and microvascular complications in patients with type 1 diabetes (T1D). METHODS: A total of 157 patients (59 M/98 W; age 39.1 ± 14.8 years) with T1D who switched from multiple daily injections to CSII and used CSII for at least one year were included. HbA1c levels and status of microvascular complications before and while under CSII were analyzed, retrospectively. RESULTS: The follow-up period was 4.0 ± 1.5 years. HbA1c significantly decreased from 8.4 ± 1.3 to 7.7 ± 1.3% (68 ± 14 to 61 ± 14 mmol/mol) after 1-year CSII and remained lower than pre-CSII levels during four years. Patients with pre-CSII HbA1c >8.0% (64 mmol/mol) showed significant improvement of HbA1c for four years, while those with pre-CSII HbA1c <8.0% showed no significant change. The prevalence of retinopathy, albuminuria, and chronic kidney disease (CKD) were respectively 39%, 12%, and 9% at CSII initiation. During follow-up, the incidence of retinopathy, albuminuria, and CKD were 3.6, 2.5 and 1.4/100 patient-years. Onset or progression of retinopathy occurred in 16 (27.1%) patients with diabetes duration >15 years, and in three (4.3%) patients with diabetes duration <15 years ( P < .01). CONCLUSION: CSII was effective in improving HbA1c for up to four years, specifically in patients with HbA1c >8% (64 mmol/mol) prior to CSII. Incidence and progression rates of retinopathy and albuminuria were low, particularly in patients with a diabetes duration <15 years at CSII initiation. These results argue for not delaying a proposal of CSII initiation in T1D with sustained HbA1c >8% (64 mmol/mol).
Authors: Peter Hovind; Lise Tarnow; Kasper Rossing; Peter Rossing; Stefanie Eising; Nicolai Larsen; Christian Binder; Hans-Henrik Parving Journal: Diabetes Care Date: 2003-04 Impact factor: 19.112
Authors: K Jeitler; K Horvath; A Berghold; T W Gratzer; K Neeser; T R Pieber; A Siebenhofer Journal: Diabetologia Date: 2008-03-20 Impact factor: 10.122
Authors: G Lepore; D Bruttomesso; M Bonomo; A R Dodesini; S Costa; E Meneghini; A Corsi; I Nosari; R Trevisan Journal: Diabet Med Date: 2009-06 Impact factor: 4.359
Authors: Laura J Reid; Fraser W Gibb; Helen Colhoun; Sarah H Wild; Mark W J Strachan; Karen Madill; Baljean Dhillon; Shareen Forbes Journal: Diabetologia Date: 2021-05-08 Impact factor: 10.122